Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: An evidence-based review of its place in therapy

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 2263-2270

  Hayes, Jennifer ^a   Anderson, Rosie ^a   Stephens, Jeffrey W ^a,b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Fixed dose combination; Metformin; Sitagliptin; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; EXENDIN 4; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS SITAGLIPTIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE;

ADD ON THERAPY; AREA UNDER THE CURVE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FUNGAL GENITAL INFECTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION; ANIMAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE;

ANIMALS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; METFORMIN; SITAGLIPTIN PHOSPHATE;

EID: 84983348682     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S93076     Document Type: Review

References (34)

1. National Institute for Health and Care Excellence. Type 2 Diabetes in Adults: Management. 2015 NICE guideline (NG28). Available from: http://www.nice.org.uk/guidance/ng28?unlid=9428993482016126103832. Accessed July 1, 2016.
2. American Diabetes Association. Standards of medical care in diabetes–2016. Diabetes Care. 2016;39(suppl 1):S1–S106.
3. Herman G, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–688.
4. Papanas N, Maltezis E. Metformin: a review of its use in the treatment of type 2 diabetes. Clin Med Ther. 2009;1:1367–1381.
5. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33(5):511–527.
6. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res. 2004;36(11–12):804–810.
7. Golightly LK, Drayana CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51(8):501–514.
8. Bergenstal RM, Wysham C, MacConell L, et al; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–439.
9. Chwieduk CM. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Drugs. 2011;71(3):349–361.
10. National Center for Biotechnology Information. PubChem Compound Database; CID=4091. Available from: http://pubchem.ncbi.nlm.nih.gov/compound/4091. Accessed January 2016.
11. National Center for Biotechnology Information. PubChem Compound Database; CID=4369359. Available from: http://pubchem.ncbi.nlm.nih.gov/compound/4369359. Accessed January 2016.
12. Herman GA, Bergman A, Yi B, Kipnes M; Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22(10):1939–1947.
13. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin in therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(2):537–550.
14. Brazg R, Xu L, Dalla MC, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-hour glycemic control and B-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):186–193.
15. Aschner P, Chan J, Owens D, et al; EASIE investigators. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012;379(9833):2262–2269.
16. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res. 2004;36(11–12):804–810.
17. Williams-Herman D, Xu L, Teng R, et al. Effect of initial combination therapy with sitagliptin and metformin on B-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(1):67–76.
18. Reasner C, Olansky L, Seck T, et al. The effect of initial therapy with the fixed–dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–652.
19. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(5):442–451.
20. Goldstein B, Feinglos M, Lunceford J, Johnson J, Williams-Herman D; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987.
21. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–2643.
22. Nauck M, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–206.
23. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562–576.
24. Karasik A, Wu M, Williams-Herman D, et al. Sitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycemia and with weight loss [abstract no. 523-P (plus poster)]. 67th Scientific Sessions of the American Diabetes Association; Jun 22–26, 2007; Chicago, IL, A139.
25. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160–168.
26. Bergenstal R, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther. 2012;3(1):13.
27. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508–2515.
28. Vilsboll J, Rosenstock H, Jarvinen Y, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes T. Diabetes Obes Metab. 2010;12(2):167–177.
29. Januvia (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck; 2011. Available from: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf. Accessed December 2015.
30. Li L, Shen J, Bala M, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus:systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;345:g2366.
31. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin. Diabetes Care. 2010;33(11):2349–2354.
32. Heaf J. Metformin in chronic kidney disease: time for a rethink. Perit Dial Int. 2014;34(4):353–357.
33. Chan J, Scott R, Arjona Ferreira J, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545–555.
34. Joint Formulary Committee [homepage on the Internet]. British National Formulary. London: BMJ Group and Pharmaceutical. Available from: www.medicinescomplete.com. Accessed January 2016.